Publicaciones en colaboración con investigadores/as de Hospital Universitario Marqués de Valdecilla (18)

2024

  1. Neddylation inhibition prevents acetaminophen-induced liver damage by enhancing the anabolic cardiolipin pathway

    Cell Reports Medicine, Vol. 5, Núm. 7

2022

  1. Inhibition of ATG3 ameliorates liver steatosis by increasing mitochondrial function

    Journal of Hepatology, Vol. 76, Núm. 1, pp. 11-24

  2. Inhibition of carnitine palmitoyltransferase 1A in hepatic stellate cells protects against fibrosis

    Journal of Hepatology, Vol. 77, Núm. 1, pp. 15-28

  3. Metabolic-associated fatty liver disease: From simple steatosis toward liver cirrhosis and potential complications. Proceedings of the Third Translational Hepatology Meeting, organized by the Spanish Association for the Study of the Liver (AEEH)

    Gastroenterologia y Hepatologia, Vol. 45, Núm. 9, pp. 724-734

  4. Mitochondrial bioenergetics boost macrophage activation, promoting liver regeneration in metabolically compromised animals

    Hepatology, Vol. 75, Núm. 3, pp. 550-566

  5. Neddylation tunes peripheral blood mononuclear cells immune response in COVID-19 patients

    Cell Death Discovery, Vol. 8, Núm. 1

  6. Restoring cellular magnesium balance through Cyclin M4 protects against acetaminophen-induced liver damage

    Nature Communications, Vol. 13, Núm. 1

2021

  1. Boosting mitochondria activity by silencing MCJ overcomes cholestasis-induced liver injury

    JHEP Reports, Vol. 3, Núm. 3

  2. E2F1 and E2F2-mediated repression of CPT2 establishes a lipid-rich tumor-promoting environment

    Cancer Research, Vol. 81, Núm. 11, pp. 2874-2887

  3. Magnesium accumulation upon cyclin M4 silencing activates microsomal triglyceride transfer protein improving NASH

    Journal of Hepatology, Vol. 75, Núm. 1, pp. 34-45

  4. Neddylation inhibition ameliorates steatosis in NAFLD by boosting hepatic fatty acid oxidation via the DEPTOR-mTOR axis

    Molecular Metabolism, Vol. 53

2020

  1. Silencing hepatic MCJ attenuates non-alcoholic fatty liver disease (NAFLD) by increasing mitochondrial fatty acid oxidation

    Nature Communications, Vol. 11, Núm. 1

  2. Targeting Hepatic Glutaminase 1 Ameliorates Non-alcoholic Steatohepatitis by Restoring Very-Low-Density Lipoprotein Triglyceride Assembly

    Cell Metabolism, Vol. 31, Núm. 3, pp. 605-622.e10

2019

  1. miR-873-5p targets mitochondrial GNMT-Complex II interface contributing to non-alcoholic fatty liver disease

    Molecular Metabolism, Vol. 29, pp. 40-54

2018

  1. MiR-873-5p acts as an epigenetic regulator in early stages of liver fibrosis and cirrhosis

    Cell Death and Disease, Vol. 9, Núm. 10

2017

  1. A morphological method for ammonia detection in liver

    PLoS ONE, Vol. 12, Núm. 3

  2. Deregulated neddylation in liver fibrosis

    Hepatology, Vol. 65, Núm. 2, pp. 694-709

  3. The mitochondrial negative regulator MCJ is a therapeutic target for acetaminophen-induced liver injury

    Nature Communications, Vol. 8, Núm. 1